Kamada (NASDAQ:KMDA) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Kamada (NASDAQ:KMDA) in a report published on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $18.00 price objective on the biotechnology company’s stock.

A number of other brokerages have also recently commented on KMDA. HC Wainwright reaffirmed a buy rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, May 9th. StockNews.com started coverage on shares of Kamada in a report on Thursday, June 27th. They set a buy rating for the company.

Kamada Stock Performance

Shares of KMDA stock opened at $5.15 on Wednesday. The firm’s 50 day moving average price is $5.26 and its two-hundred day moving average price is $5.61. The stock has a market cap of $296.02 million, a PE ratio of 22.39 and a beta of 1.06. Kamada has a 52-week low of $4.08 and a 52-week high of $6.53.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.02). The company had revenue of $37.74 million during the quarter, compared to the consensus estimate of $38.01 million. Kamada had a return on equity of 5.50% and a net margin of 8.33%. As a group, sell-side analysts predict that Kamada will post 0.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kamada

Large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares during the period. Calton & Associates Inc. bought a new stake in Kamada in the 4th quarter valued at $111,000. Aristides Capital LLC boosted its stake in Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 16,635 shares during the period. Y.D. More Investments Ltd increased its holdings in Kamada by 107.1% during the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 15,000 shares in the last quarter. Finally, EWA LLC acquired a new stake in shares of Kamada in the 4th quarter valued at about $68,000. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.